Design and Characterization of Thermosensitive Niosomes as Platforms for Daunorubicin Delivery
Authors:
- Viliana GuglevaViliana Gugleva
- Katerina AhchiyskaKAKaterina Ahchiyska
- Elena Drakalska-SersemovaEDElena Drakalska-Sersemova
- Rositsa MihaylovaRMRositsa Mihaylova
- Natalia Toncheva-MonchevaNTNatalia Toncheva-Moncheva
- Erik DimitrovEDErik Dimitrov
- Krum AleksandrovKAKrum Aleksandrov
- Aleksander ForysAleksander Forys
- Barbara TrzebickaBarbara Trzebicka
- Denitsa MomekovaDMDenitsa Momekova
Open Access
- 15 September 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (9) , 1375
Abstract
Background/Objectives: The study describes the elaboration and evaluation of thermosensitive niosomes intended for the systemic application of daunorubicin hydrochloride. The attained stimulus sensitivity would determine the release of the chemotherapeutic predominantly at the target site, which ensures a higher drug concentration and leads to reduced systemic toxicity. The latter is highly beneficial, as the anthracycline antibiotic is known for its dose-dependent cardiotoxic effects. Methods: Conventional and copolymer-modified niosomes were prepared via thin-film hydration and the transmembrane ammonium gradient method, allowing us to assess the impacts of copolymer type-DHP-PiPOX (1,3-dihexadecyl-propane-2-ol-poly(2-isopropyl-2-oxazoline)) or DHP-PETEGA (1,3-dihexadecyl-propane-2-ol-poly(ethoxytriethylene glycol acrylate)) and their concentrations (0.5, 1, and 2.5 mol%), as well as the method of preparation, on the main physicochemical properties of the vesicles. Niosomes were characterized in terms of their size, polydispersity index (PDI), zeta potential, entrapment efficiency, morphology, and drug release properties. Thermosensitivity was evaluated by fluorescence studies, and the antiproliferative activity of optimized formulations was assessed against the acute myelocyte leukemia-derived HL-60 cell line. Results: Daunorubicin-loaded niosomes modified with DHP-PiPOX and DHP-PETEGA at 2.5 mol% exhibited suitable physicochemical properties for systemic application, with sizes below 200 nm (155 and 158 nm respectively), low PDI values of 0.25 and 0.29, spherical morphology, and high daunorubicin entrapment efficiency (68.6 and 66.5% respectively). The vesicles showed temperature-dependent drug release properties and superior antiproliferative activity compared to the free daunorubicin (IC50 values of 6.91 and 8.54 vs. 12.14). Conclusions: The obtained results indicate that the developed thermosensitive nanovesicles may serve as a suitable drug delivery system for the systemic application of daunorubicin hydrochloride.Keywords
Funding Information
- National Recovery and Resilience Plan of the Republic of Bulgaria (BGRRP-2.004-0004-C01)
This publication has 31 references indexed in Scilit:
- Liposomes and liposome-like nanoparticles: From anti-fungal infection to the COVID-19 pandemic treatmentAsian Journal of Pharmaceutical Sciences, 2022
- Smart drug delivery systems for precise cancer therapyActa Pharmaceutica Sinica B, 2022
- Functionalized niosomes as a smart delivery device in cancer and fungal infectionEuropean Journal of Pharmaceutical Sciences, 2022
- Spontaneous temperature-sensitive Pluronic ® based niosomes: Triggered drug release using mild hyperthermiaInternational Journal of Pharmaceutics, 2016
- Molecular structure and dynamical properties of niosome bilayers with and without cholesterol incorporation: A molecular dynamics simulation studyApplied Surface Science, 2016
- Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneityAdvanced Drug Delivery Reviews, 2015
- Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acidInternational Journal of Pharmaceutics, 2012
- Formation of mesoglobules in aqueous media from thermo-sensitive poly(ethoxytriethyleneglycol acrylate)Polymer Bulletin, 2011
- Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979)Cancer Chemotherapy and Pharmacology, 2004
- Kompendium Internistische Onkologie1996